Literature DB >> 11513169

Helicobacter pylori and gastric lymphoma: high seroprevalence of CagA in diffuse large B-cell lymphoma but not in low-grade lymphoma of mucosa-associated lymphoid tissue type.

J C Delchier1, D Lamarque, M Levy, E M Tkoub, C Copie-Bergman, L Deforges, M T Chaumette, C Haioun.   

Abstract

OBJECTIVE: Gastric lymphoma of mucosa-associated lymphoid tissue (MALT) type is closely related to Helicobacter pylori (H. pylori) infection. In vitro studies have demonstrated H. pylori-induced B cell proliferation to be strain dependent. High prevalences of CagA protein and FldA protein have been reported in strains obtained from patients with gastric lymphoma of MALT type. The aims of the present study were to evaluate the prevalence of H. pylori infection and to search for antigenic particularities in 53 patients with primary gastric lymphoma in comparison with a group of infected patients with benign disease.
METHODS: Of the 53 patients, 37 presented with low-grade lymphoma of MALT type (LGLM) and 16 with diffuse large B-cell lymphoma (DLBCL). They were compared to a group of 162 H. pylori-infected subjects comprising the control group: 111 had gastric or duodenal ulcer (GDU) and 51 nonulcer dyspepsia (NUD). Diagnosis of gastric lymphoma was established on histological examination of endoscopic specimens. Anti-H. pylori antibodies were assayed by third-generation ELISA. Western blot assay was used to detect antibodies against nine antigens (including CagA protein), which were recognized on the basis of their molecular weight.
RESULTS: Of the 53 patients with gastric lymphoma, 45 were H. pylori-positive (85%): of these, 25 (56.5%) had anti-CagA antibodies. The prevalence of H. pylori seropositivity was 78% (29/37) in LGLM and 100% (16/16) in DLBCL. The prevalence of CagA seropositivity in H. pylori-positive patients was 44.8% (13/29) and 75% (12/16), respectively (p < 0.05). In comparison, the seroprevalence of CagA was 77.4% (86/111) in GDU patients and 43.1% (22/53) in NUD patients. The prevalence of antibodies to other antigenic proteins detected with Helicoblot 2.0 (19.5kd, 30kd, 35kd, VacA, HSPb, Urease A, and Urease B) did not differ among the groups except for 35kd protein, which was significantly higher (p < 0.01) in GDU than in NUD and in LGLM (76.6% vs 49% and 46.7%).
CONCLUSION: These findings suggest that in patients who develop gastric lymphomas in response to H. pylori, virulent strains expressing CagA protein are preferentially associated with DLBCL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513169     DOI: 10.1111/j.1572-0241.2001.04036.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

1.  Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries.

Authors:  Seiji Shiota; Osamu Matsunari; Masahide Watada; Yoshio Yamaoka
Journal:  Future Microbiol       Date:  2010-12       Impact factor: 3.165

2.  Diagnosis of Helicobacter pylori infection and diseases associated with Helicobacter pylori by Helicobacter pylori outer membrane proteins.

Authors:  Zheng Jiang; Ai-Long Huang; Xiao-Hong Tao; Pi-Long Wang
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

3.  Recombinant Helicobacter pylori catalase.

Authors:  Yang Bai; Ya-Li Zhang; Jian-Feng Jin; Ji-De Wang; Zhao-Shan Zhang; Dian-Yuan Zhou
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

4.  The best method of detecting prior Helicobacter pylori infection.

Authors:  Chien-Yu Lu; Chao-Hung Kuo; Yi-Ching Lo; Hung-Yi Chuang; Yuan-Chieh Yang; I-Chen Wu; Fang-Jong Yu; Yi-Chen Lee; Chang-Ming Jan; Wen-Ming Wang; Deng-Chyang Wu
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

5.  New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis.

Authors:  Kevin David Shield; Claire Marant Micallef; Catherine de Martel; Isabelle Heard; Francis Megraud; Martyn Plummer; Jérôme Vignat; Freddie Bray; Isabelle Soerjomataram
Journal:  Eur J Epidemiol       Date:  2017-12-06       Impact factor: 8.082

6.  Construction and characterization of bivalent vaccine candidate expressing HspA and M(r)18,000 OMP from Helicobacter pylori.

Authors:  Zheng Jiang; Ai-Long Huang; Xiao-Hong Tao; Pi-Long Wang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

7.  Marginal Zone B-cell Lymphoma (MALT Lymphoma).

Authors:  Patrick D. Hung; Mitchell L. Schubert; Anastasios A. Mihas
Journal:  Curr Treat Options Gastroenterol       Date:  2004-04

8.  Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Philippe Lehours; Armelle Ménard; Sandrine Dupouy; Bernard Bergey; Fréderique Richy; Frank Zerbib; Agnès Ruskoné-Fourmestraux; Jean Charles Delchier; Francis Mégraud
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

9.  Clinicopathologic study of mucosa-associated lymphoid tissue lymphoma in gastroscopic biopsy.

Authors:  Hong Cheng; Jun Wang; Chuan-Shan Zhang; Pei-Song Yan; Xiao-Hui Zhang; Pei-Zhen Hu; Fu-Cheng Ma
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

10.  Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance.

Authors:  S-H Kuo; L-T Chen; C-W Lin; M-S Wu; P-N Hsu; H-J Tsai; C-Y Chu; Y-S Tzeng; H-P Wang; K-H Yeh; A-L Cheng
Journal:  Blood Cancer J       Date:  2013-07-12       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.